

DEC 04 2001

Reply and Amendment
U.S. Serial No. 09 292,053
Attorney Docket No. 037003-0275739

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

RECEIVED

DEC 05 2001

TECH CENTER 1600 2900

In re Patent Application of:)
)
Mitchell E. Reff, et al.)
)
Application No. 09/292,053)
)
Filed: April 14, 1998)
)
For: GAMMA-1 ANTI-HUMAN CD23)
MONOCLONAL ANTIBODIES)
AND USE THEREOF AS)
THERAPEUTICS)

Group Art Unit: 1644

Examiner: M. DiBrino

REPLY AND AMENDMENTS PURSUANT TO 37 CFR §1.116

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action [final rejection] kindly amend the above-identified application as follows:

IN THE CLAIMS

Kindly amend Claims 38, 46, and 47 as set forth below:

38. (Amended) A method of inhibiting IgE in a human subject in need of such inhibition comprising administering an IgE inhibiting effective amount of an anti-human CD23 antibody comprising a human gamma-1 constant region.

46. (Amended) The method of Claim 38, wherein the anti-human CD23 antibody comprises a variable heavy domain having a sequence selected from the group consisting of the polypeptide encoded by a nucleic acid sequence having SEQ ID NO:3, SEQ ID NO:7; and a variable light domain having a sequence selected from the group consisting of the polypeptide encoded by a nucleic acid sequence having SEQ ID NO:1 and SEQ ID NO:5.

Please do
not enter
MES
initials